Jon Congleton, Mineralys CEO
June 8, 2022 10:47 AM EDT
Financing
Startups

RA Cap­i­tal backs a Philly biotech's $118M crossover as it aims to break in­to the hy­per­ten­sion space

Tyler Patchen

News Reporter

While the hy­per­ten­sion mar­ket be­comes ever more crowd­ed with can­di­dates as J&J toss­es its hat in­to the ring, a Penn­syl­va­nia-based start­up is look­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times